Phases of trials - Revision history

Lawrence: /* Conclusion */

2025-06-04T11:55:51Z

Conclusion

← Older revision		Revision as of 11:55, 4 June 2025
Line 103:		Line 103:
	----		----

	''Adapted for educational ~~purposes~~. Please cite ~~appropriate~~ sources when using this material in research or teaching.''		=== Bibliography ===

			# U.S. Food and Drug Administration (FDA). The Drug Development Process: Step 3 – Clinical Research. Available from: https://www.fda.gov
			# Chow S-C, Liu JP. Design and [[Analysis]] of Clinical Trials: Concepts and Methodologies. 3rd ed. Wiley; 2013. Chapter 2: Clinical trial phases and regulatory framework.
			# van Norman GA. Drugs, devices, and the FDA: Part 1. An overview of approval processes for drugs. ''JACC: Basic to Translational Science''. 2016;1(3):170–179.
			# Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. ''Nature Reviews Drug Discovery''. 2008;7(1):13–14. Discusses operational characteristics of different trial phases.
			# ICH Harmonised Guideline. General Considerations for Clinical Studies E8(R1). International Council for Harmonisation; 2019. Describes objectives and design considerations by phase.

			----
			''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence at 22:40, 29 March 2025

2025-03-29T22:40:03Z

← Older revision		Revision as of 22:40, 29 March 2025
Line 1:		Line 1:
	= Phases of trials =		= Phases of trials =

	Clinical trials are commonly conducted in phases, each with a distinct purpose, scope, and methodology. Understanding these phases helps clarify where a trial fits within the larger research pipeline, from early safety assessments to widespread implementation.		Clinical trials are commonly conducted in phases, each with a distinct purpose, scope, and methodology. Understanding these phases helps clarify where a trial fits within the larger research pipeline, from early safety assessments to widespread implementation.

	== Phase 0: Exploratory (Microdosing) Trials ==		== Phase 0: Exploratory (Microdosing) Trials ==
	Also known as “[[First-in-man trials\|first-in-human]]” studies.
			Also known as “[[:First-in-man trials\|first-in-human]]” studies.
	Phase 0 trials are optional early-phase studies involving very small doses of a drug (sub-therapeutic) given to a small number of participants, usually fewer than 15.		Phase 0 trials are optional early-phase studies involving very small doses of a drug (sub-therapeutic) given to a small number of participants, usually fewer than 15.
	Purpose:
	• Assess pharmacokinetics (PK) and pharmacodynamics (PD)		'''Purpose:'''
	• Inform go/no-go decisions before Phase I		* Assess pharmacokinetics (PK) and pharmacodynamics (PD)
	Key Features:		* Inform go/no-go decisions before Phase I
	• Non-therapeutic
	• No clinical benefit expected		'''Key Features:'''
	• Helps identify promising candidates for further testing		* Non-therapeutic
			* No clinical benefit expected
			* Helps identify promising candidates for further testing

	== Phase I: Safety and Dose-Finding ==		== Phase I: Safety and Dose-Finding ==

	Phase I trials are the first stage of testing in humans, usually involving 20–100 healthy volunteers or patients (for high-risk drugs like cancer treatments).		Phase I trials are the first stage of testing in humans, usually involving 20–100 healthy volunteers or patients (for high-risk drugs like cancer treatments).
	Purpose:
	• Assess safety and tolerability		'''Purpose:'''
	• Determine safe dosage range		* Assess safety and tolerability
	• Identify side effects		* Determine safe dosage range
	Design Elements:		* Identify side effects
	• Open-label or dose-escalation design (e.g., 3+3 or Bayesian adaptive models)
	• Focus on maximum tolerated dose (MTD)		'''Design Elements:'''
			* Open-label or dose-escalation design (e.g., 3+3 or Bayesian adaptive models)
			* Focus on maximum tolerated dose (MTD)

	== Phase II: Efficacy and Side Effects ==		== Phase II: Efficacy and Side Effects ==

	Phase II trials further evaluate the efficacy of an intervention and continue to assess its safety, typically in 100–300 participants with the target condition.		Phase II trials further evaluate the efficacy of an intervention and continue to assess its safety, typically in 100–300 participants with the target condition.
	Purpose:
	• Preliminary evidence of clinical effect		'''Purpose:'''
	• Continued safety assessment		* Preliminary evidence of clinical effect
	• Optimal dosing		* Continued safety assessment
	Design Elements:		* Optimal dosing
	• Often randomized and controlled
	• May use surrogate outcomes		'''Design Elements:'''
	• Can be split into Phase IIa (dose exploration) and Phase IIb (efficacy confirmation)		* Often randomized and controlled
			* May use surrogate outcomes
			* Can be split into Phase IIa (dose exploration) and Phase IIb (efficacy confirmation)

	== Phase III: Confirmatory Efficacy Trials ==		== Phase III: Confirmatory Efficacy Trials ==

	Phase III trials are large-scale RCTs involving hundreds to thousands of participants across multiple sites. These trials provide the definitive evidence needed for regulatory approval.		Phase III trials are large-scale RCTs involving hundreds to thousands of participants across multiple sites. These trials provide the definitive evidence needed for regulatory approval.
	Purpose:
	• Confirm therapeutic benefit		'''Purpose:'''
	• Compare to standard of care		* Confirm therapeutic benefit
	• Identify less common side effects		* Compare to standard of care
	• Establish risk-benefit profile		* Identify less common side effects
	Design Elements:		* Establish risk-benefit profile
	• Often multicenter, randomized, double-blind
	• Pre-specified primary hypothesis		'''Design Elements:'''
	• May include interim analyses and data safety monitoring boards (DSMBs)		* Often multicenter, randomized, double-blind
			* Pre-specified primary hypothesis
			* May include interim analyses and data safety monitoring boards (DSMBs)

	== Phase IV: Post-Marketing Surveillance ==		== Phase IV: Post-Marketing Surveillance ==

	Phase IV trials are conducted after regulatory approval to monitor the long-term effectiveness and safety of a treatment in real-world settings.		Phase IV trials are conducted after regulatory approval to monitor the long-term effectiveness and safety of a treatment in real-world settings.
	Purpose:
	• Detect rare or long-term adverse effects		'''Purpose:'''
	• Study effectiveness in diverse populations		* Detect rare or long-term adverse effects
	• Assess cost-effectiveness and quality of life		* Study effectiveness in diverse populations
	Design Elements:		* Assess cost-effectiveness and quality of life
	• Observational or pragmatic RCTs
	• May be mandated by regulators		'''Design Elements:'''
	• Often use registry data or health records		* Observational or pragmatic RCTs
			* May be mandated by regulators
			* Often use registry data or health records

	== Summary Table ==		== Summary Table ==
Line 72:		Line 89:
	\|}		\|}

			== Integration with Trial Design ==

	~~== Integration with Trial Design ==~~
	The phase of a trial often influences the:		The phase of a trial often influences the:
	• Type of hypothesis tested ([[Hypothesis]])		* Type of hypothesis tested ([[Hypothesis]])
	• Level of monitoring and oversight		* Level of monitoring and oversight
	• Statistical methods used		* Statistical methods used
	• Ethical considerations (e.g., acceptable risk-benefit ratio)		* Ethical considerations (e.g., acceptable risk-benefit ratio)

	== Conclusion ==		== Conclusion ==

	Understanding the phases of clinical trials is essential for designing, conducting, and interpreting research appropriately. Each phase serves a distinct purpose in the journey from bench to bedside, ensuring that interventions are safe, effective, and beneficial to patients.		Understanding the phases of clinical trials is essential for designing, conducting, and interpreting research appropriately. Each phase serves a distinct purpose in the journey from bench to bedside, ensuring that interventions are safe, effective, and beneficial to patients.

	----		----

	''Adapted for educational purposes. Please cite appropriate sources when using this material in research or teaching.''		''Adapted for educational purposes. Please cite appropriate sources when using this material in research or teaching.''

Lawrence at 22:29, 29 March 2025

2025-03-29T22:29:09Z

← Older revision		Revision as of 22:29, 29 March 2025
Line 81:		Line 81:
	== Conclusion ==		== Conclusion ==
	Understanding the phases of clinical trials is essential for designing, conducting, and interpreting research appropriately. Each phase serves a distinct purpose in the journey from bench to bedside, ensuring that interventions are safe, effective, and beneficial to patients.		Understanding the phases of clinical trials is essential for designing, conducting, and interpreting research appropriately. Each phase serves a distinct purpose in the journey from bench to bedside, ensuring that interventions are safe, effective, and beneficial to patients.
	---
			----
	''Adapted for educational purposes. Please cite appropriate sources when using this material in research or teaching.''		''Adapted for educational purposes. Please cite appropriate sources when using this material in research or teaching.''

Lawrence at 22:26, 29 March 2025

2025-03-29T22:26:57Z

← Older revision		Revision as of 22:26, 29 March 2025
Line 57:		Line 57:

	== Summary Table ==		== Summary Table ==
	Phase Primary Goal Participants Design Focus
	Phase 0 PK/PD, feasibility <15 Microdosing, no therapeutic intent		{\| class="wikitable"
	Phase I Safety, dose range 20–100 Dose-escalation, tolerability		! Phase !! Primary Goal !! Participants !! Design Focus
	Phase II Preliminary efficacy 100–300 Controlled, surrogate outcomes		\|-
	Phase III Confirm efficacy, safety 300–3000+ Hypothesis-driven, regulatory-focused		\| Phase 0 \|\| PK/PD, feasibility \|\| <15 \|\| Microdosing, no therapeutic intent
	Phase IV Long-term effects, safety Thousands Real-world, post-approval		\|-
			\| Phase I \|\| Safety, dose range \|\| 20–100 \|\| Dose-escalation, tolerability
			\|-
			\| Phase II \|\| Preliminary efficacy \|\| 100–300 \|\| Controlled, surrogate outcomes
			\|-
			\| Phase III \|\| Confirm efficacy, safety \|\| 300–3000+ \|\| Hypothesis-driven, regulatory-focused
			\|-
			\| Phase IV \|\| Long-term effects, safety \|\| Thousands \|\| Real-world, post-approval
			\|}


	== Integration with Trial Design ==		== Integration with Trial Design ==

Lawrence: Created page with "= Phases of trials = Clinical trials are commonly conducted in phases, each with a distinct purpose, scope, and methodology. Understanding these phases helps clarify where a trial fits within the larger research pipeline, from early safety assessments to widespread implementation. == Phase 0: Exploratory (Microdosing) Trials == Also known as “first-in-human” studies. Phase 0 trials are optional early-phase studies involving very small doses of..."

2025-03-29T22:23:23Z

Created page with "= Phases of trials = Clinical trials are commonly conducted in phases, each with a distinct purpose, scope, and methodology. Understanding these phases helps clarify where a trial fits within the larger research pipeline, from early safety assessments to widespread implementation. == Phase 0: Exploratory (Microdosing) Trials == Also known as “first-in-human” studies. Phase 0 trials are optional early-phase studies involving very small doses of..."

New page

= Phases of trials =
Clinical trials are commonly conducted in phases, each with a distinct purpose, scope, and methodology. Understanding these phases helps clarify where a trial fits within the larger research pipeline, from early safety assessments to widespread implementation.
== Phase 0: Exploratory (Microdosing) Trials ==
Also known as “[[First-in-man trials|first-in-human]]” studies.
Phase 0 trials are optional early-phase studies involving very small doses of a drug (sub-therapeutic) given to a small number of participants, usually fewer than 15.
Purpose:
• Assess pharmacokinetics (PK) and pharmacodynamics (PD)
• Inform go/no-go decisions before Phase I
Key Features:
• Non-therapeutic
• No clinical benefit expected
• Helps identify promising candidates for further testing

== Phase I: Safety and Dose-Finding ==
Phase I trials are the first stage of testing in humans, usually involving 20–100 healthy volunteers or patients (for high-risk drugs like cancer treatments).
Purpose:
• Assess safety and tolerability
• Determine safe dosage range
• Identify side effects
Design Elements:
• Open-label or dose-escalation design (e.g., 3+3 or Bayesian adaptive models)
• Focus on maximum tolerated dose (MTD)

== Phase II: Efficacy and Side Effects ==
Phase II trials further evaluate the efficacy of an intervention and continue to assess its safety, typically in 100–300 participants with the target condition.
Purpose:
• Preliminary evidence of clinical effect
• Continued safety assessment
• Optimal dosing
Design Elements:
• Often randomized and controlled
• May use surrogate outcomes
• Can be split into Phase IIa (dose exploration) and Phase IIb (efficacy confirmation)

== Phase III: Confirmatory Efficacy Trials ==
Phase III trials are large-scale RCTs involving hundreds to thousands of participants across multiple sites. These trials provide the definitive evidence needed for regulatory approval.
Purpose:
• Confirm therapeutic benefit
• Compare to standard of care
• Identify less common side effects
• Establish risk-benefit profile
Design Elements:
• Often multicenter, randomized, double-blind
• Pre-specified primary hypothesis
• May include interim analyses and data safety monitoring boards (DSMBs)

== Phase IV: Post-Marketing Surveillance ==
Phase IV trials are conducted after regulatory approval to monitor the long-term effectiveness and safety of a treatment in real-world settings.
Purpose:
• Detect rare or long-term adverse effects
• Study effectiveness in diverse populations
• Assess cost-effectiveness and quality of life
Design Elements:
• Observational or pragmatic RCTs
• May be mandated by regulators
• Often use registry data or health records

== Summary Table ==
Phase Primary Goal Participants Design Focus
Phase 0 PK/PD, feasibility <15 Microdosing, no therapeutic intent
Phase I Safety, dose range 20–100 Dose-escalation, tolerability
Phase II Preliminary efficacy 100–300 Controlled, surrogate outcomes
Phase III Confirm efficacy, safety 300–3000+ Hypothesis-driven, regulatory-focused
Phase IV Long-term effects, safety Thousands Real-world, post-approval

== Integration with Trial Design ==
The phase of a trial often influences the:
• Type of hypothesis tested ([[Hypothesis]])
• Level of monitoring and oversight
• Statistical methods used
• Ethical considerations (e.g., acceptable risk-benefit ratio)
== Conclusion ==
Understanding the phases of clinical trials is essential for designing, conducting, and interpreting research appropriately. Each phase serves a distinct purpose in the journey from bench to bedside, ensuring that interventions are safe, effective, and beneficial to patients.
---
''Adapted for educational purposes. Please cite appropriate sources when using this material in research or teaching.''